{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:39:32Z","timestamp":1792431572575,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate temporal trends in medication-assisted treatment use among pregnant women with opioid use disorder.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We conducted a retrospective cohort study using Pennsylvania Medicaid administrative data. Trends in medication-assisted treatment use, opioid pharmacotherapy (methadone and buprenorphine) and behavioral health counselling, were calculated using pharmacy records and procedure codes. Cochrane-Armitage tests evaluated linear trends in characteristics of pregnant women using methadone compared with buprenorphine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>In total, we evaluated 12,587 pregnancies among 10,741 women with opioid use disorder who had a live birth between 2009 and 2015. Across all years, 44.1% of pregnant women received no opioid pharmacotherapy, 27.1% used buprenorphine, and 28.8% methadone. Fewer than half of women had any behavioral health counseling during pregnancy. The adjusted prevalence of methadone use declined from 31.6% (95% CI 29.3\u201333.9%) in 2009 to 25.2% (95% CI 23.3\u201327.1%) in 2015, whereas the adjusted prevalence of buprenorphine use increased from 15.8% (95% CI 13.9\u201317.8%) to 30.9% (95% CI 28.8\u201333.0%). Greater increases in buprenorphine use were found in geographic regions with large metropolitan centers, such as the Southwest (plus 24.9%) and the Southeast (plus 12.0%), compared with largely rural regions, such as the New West (plus 5.2%). In 2015, the adjusted number of behavioral health counseling visits during pregnancy was 3.4 (95% CI 2.6\u20134.1) among women using buprenorphine, 4.0 (95% CI 3.3\u20134.7) among women who did not use pharmacotherapy, and 6.4 (95% CI 4.9\u20137.9) among women using methadone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Buprenorphine use among Medicaid-enrolled pregnant women with opioid use disorder increased significantly over time, with a small concurrent decline in methadone use. Behavioral health counseling use was low, but highest among women using methadone.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003231","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T22:16:10Z","timestamp":1554848170000},"page":"943-951","source":"Crossref","is-referenced-by-count":99,"title":["Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder"],"prefix":"10.1097","volume":"133","author":[{"given":"Elizabeth E.","family":"Krans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alton Everette","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian P.","family":"Jarlenski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"845","DOI":"10.15585\/mmwr.mm6731a1","article-title":"Opioid use disorder documented at delivery hospitalization\u2014United States, 1999\u20132014","volume":"67","author":"Haight","year":"2018","journal-title":"Morb Mortal Wkly Rep"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. American College of Obstetricians and Gynecologists","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ADM.0000000000000308","article-title":"Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance","volume":"11","author":"Klaman","year":"2017","journal-title":"J Addict Med"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ajog.2016.10.003","article-title":"Opioid dependence and pregnancy: minimizing stress on the fetal brain","volume":"216","author":"McCarthy","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/MLR.0000000000000803","article-title":"Medicaid coverage of methadone maintenance and the use of opioid agonist therapy among pregnant women in specialty treatment","volume":"55","author":"Bachhuber","year":"2017","journal-title":"Med Care"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jsat.2018.04.003","article-title":"Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States","volume":"89","author":"Short","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.whi.2013.06.006","article-title":"Medicaid covered births, 2008 through 2010, in the context of the implementation of health reform","volume":"23","author":"Markus","year":"2013","journal-title":"Womens Health Issues"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/1475-6773.12411","article-title":"Effect of medicaid expansions on health insurance coverage and access to care among low-income adults with behavioral health conditions","volume":"50","author":"Wen","year":"2015","journal-title":"Health Serv Res"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.2012.3951","article-title":"Neonatal abstinence syndrome and associated health care expenditures: United States, 2000\u20132009","volume":"307","author":"Patrick","year":"2012","journal-title":"JAMA"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ajog.2013.10.010","article-title":"Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers","volume":"210","author":"Jones","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"R18-20230711","first-page":"1","article-title":"A population-based examination of trends and disparities in medication treatment for opioid use disorders among medicaid enrollees","author":"Stein","year":"2018","journal-title":"Subst Abuse"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1377\/hlthaff.2014.1205","article-title":"Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002\u201311","volume":"34","author":"Dick","year":"2015","journal-title":"Health Aff"},{"issue":"suppl 1","key":"R21-20230711","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1360-0443.2012.04035.x","article-title":"Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review","volume":"107","author":"Jones","year":"2012","journal-title":"Addiction"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2006.01321.x","article-title":"Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study","volume":"101","author":"Fischer","year":"2006","journal-title":"Addiction"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/00952990.2017.1399403","article-title":"Medication-assisted treatment for youth with opioid use disorder: current dilemmas and remaining questions","volume":"44","author":"Chang","year":"2018","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/add.13363","article-title":"A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults","volume":"111","author":"Marsch","year":"2016","journal-title":"Addiction"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"e20161893","DOI":"10.1542\/peds.2016-1893","article-title":"Medication-assisted treatment of adolescents with opioid use disorders","volume":"138","author":"Ryan","year":"2016","journal-title":"Pediatrics"},{"key":"R27-20230711","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatr"},{"key":"R28-20230711","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1176\/ps.62.11.pss6211_1273","article-title":"Racial-ethnic disparities in substance abuse treatment: the role of criminal history and socioeconomic status","volume":"62","author":"Cook","year":"2011","journal-title":"Psychiatr Serv"},{"key":"R29-20230711","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1377\/hlthaff.2011.0983","article-title":"Blacks and Hispanics are less likely than whites to complete addiction treatment, largely due to socioeconomic factors","volume":"32","author":"Saloner","year":"2013","journal-title":"Health Aff"},{"key":"R30-20230711","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1007\/s10995-011-0923-5","article-title":"Barriers to receiving substance abuse treatment among rural pregnant women in Kentucky","volume":"16","author":"Jackson","year":"2012","journal-title":"Matern Child Health J"},{"key":"R31-20230711","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamapediatrics.2016.3750","article-title":"Rural and urban differences in neonatal abstinence syndrome and maternal opioid use, 2004 to 2013","volume":"171","author":"Villapiano","year":"2017","journal-title":"JAMA Pediatr"},{"key":"R32-20230711","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jamapsychiatry.2013.3575","article-title":"Race\/ethnicity and geographic access to medicaid substance use disorder treatment facilities in the United States","volume":"71","author":"Cummings","year":"2014","journal-title":"JAMA Psychiat"},{"key":"R33-20230711","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.2105\/AJPH.2013.301709","article-title":"Understanding the rural-urban differences in nonmedical prescription opioid use and abuse in the United States","volume":"104","author":"Keyes","year":"2014","journal-title":"Am J Public Health"},{"key":"R34-20230711","first-page":"22","article-title":"Rural healthcare disparities: challenges and solutions for the pregnant opioid-dependent population","volume":"109","author":"Lander","year":"2013","journal-title":"W V Med J"},{"key":"R35-20230711","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/AOG.0000000000000991","article-title":"Clinical, ethical, and legal considerations in pregnant women with opioid abuse","volume":"126","author":"Kremer","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R36-20230711","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American society of addiction medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"J Addict Med"},{"key":"R37-20230711","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1360-0443.2006.01362.x","article-title":"Effectiveness of drug and alcohol counselling during methadone treatment: content, frequency, and duration of counselling and association with substance use outcomes","volume":"101","author":"Gossop","year":"2006","journal-title":"Addiction"},{"key":"R38-20230711","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"N Engl J Med"},{"key":"R39-20230711","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","article-title":"The role of behavioral interventions in buprenorphine maintenance treatment: a review","volume":"174","author":"Carroll","year":"2017","journal-title":"Am J Psychiatry"},{"key":"R40-20230711","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/M18-1652","article-title":"The next stage of buprenorphine care for opioid use disorder","volume":"169","author":"Martin","year":"2018","journal-title":"Ann Intern Med"},{"key":"R43-20230711","first-page":"1","article-title":"Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states","author":"Patrick","year":"2018","journal-title":"Subst Abuse"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201905000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T18:14:57Z","timestamp":1689099297000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201905000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003231","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}